Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘FS222’

A Turning Point for IO at SITC 2024?

Choices, oh so many choices!

We’ve been following the IO wave for over a decade now and one of the questions that comes to my mind is whether we are about to experience what the Germans would call a change in times, or ‘Zeitenwende.’

The Duden German dictionary describes Zeitenwende as “the ending of an epoch or era and the beginning of a new time.”

Readers may recall it was famously used by Germany Chancellor Olaf Scholz after the Russian invasion of Ukraine in 2022 to describe how this was a turning point in European and Germany history, albeit in not necessarily a good way.

Are we at a turning point in IO for the better rather than worse?

After the initial wave of success with low hanging fruit, we’ve sadly seen more failures than successes although we’re starting to see signs that new strategies may yet deliver the promise and potential we all hoped for way back when.

In this post we take a look at 10 presentations to watch out for at SITC 2024 around the theme of Zeitenwende. Check it out!

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Another bite at the cherry

Cherry Blossom at the Edinburgh Meadows

It is very rare indeed to see first generation anti-cancer molecules hit the sweet spot against any given novel target. Those following in their wake can often learn from the experiences of their forebears and adjust accordingly.

In our latest story, we look at one such IO target with a chequered history and highlight the next generation agents coming through.

Sometimes simply switching modalities or aiming at different cells/compartments is enough to do the trick. Other times a completely different strategy is needed to unlock the riches hoped for.

With a raft of new data coming soon at ASCO, are their some new diamonds in the rough this time around?

To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

AACR21 Preview 8 – The growing bispecific niche

The first virtual 2021 AACR annual meeting starts tomorrow in earnest and we’ll be posting throughout the conference with various highlights and analysis.

There’s an explosion of new targets, novel combinatorial partners, expanding strategies and even an increasing number of companies entering the bispecific niche beyond the regular players we have covered in the past.

In our final Preview post we’re highlighting some of the AACR21 presentations which caught our attention, the science behind them, and some of questions we hope to see answered.

Stay tuned for our conference coverage and post meeting interviews!

To learn more about the hot topics at AACR21 and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

How F-star are optimising bispecific antibodies for cancer treatment

Mononclonal and bispecific antibodies in the immuno-oncology space have certainly had a bit of a roller coaster ride over the last couple of years with various safety concerns including cytokine release syndrome (CRS) and even fatalities coming to the fore following clinical holds on various compounds across several quite different compounds.

Barbara Hepworth sculpture at Downing College, Cambridge

As companies work their way through those issues with FDA and other Health Authorities, can we also learn from our previous experiences with checkpoint blockade, immune agonists and other IO targets in order to develop safer products?

One thing has become clear and that’s how important particular aspects of the engineered molecules can make an impact in terms of both safety and efficacy. There are, after all, quite a few factors that can be manipulated or changed to impact performance, much as the design arrangement and composition of various components into a unified whole is crucial to Formula Once racing cars.

In our second part of the bispecific mini-series, we head over to Europe and interview the CSO of a leading company in the IO bispecific space to learn more about these design features and the potential benefits they might induce.

It makes for rather interesting reading when we consider the next wave of IO clinical trials…

To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!